Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis

References

• Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C. (2005). Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 37:425–430.
   PubMed Web of Science ®Google Scholar
• Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, Zheng Q, Xing R, Cao Y, Rasmussen LM, Karsdal MA. (2010). A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 43:899–904.
   PubMed Web of Science ®Google Scholar
• Braun RK, Martin A, Shah S, Iwashima M, Medina M, Byrne K, Sethupathi P, Wigfield CH, Brand DD, Love RB. (2010). Inhibition of bleomycin-induced pulmonary fibrosis through pre-treatment with collagen type V. J Heart Lung Transplant 29:873–880.
   PubMedGoogle Scholar
• Breuls RGM, Klumpers DD, Everts V, Smit TH. (2009). Collagen type V modulates fibroblast behaviour dependent on substrate stiffness. Biochem Biophys Res Commun 380:425–429.
   PubMed Web of Science ®Google Scholar
• Clarià J, Jimenez W. (1999). Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. In The Liver and the Kidney, Arroyo V et al., eds. Blackwell Science, Boston, pp. 379–396.
   Google Scholar
• Combet C, Blanchet C, Geourjon C, Deléage G. (2000). NPS@: network protein sequence analysis. Trends Biochem Sci 25:147–150.
   PubMed Web of Science ®Google Scholar
• Copple BL, Allen K, Welch TP. (2010). Mechanisms of liver fibrosis. Compr Toxicol 9:263–274.
   Google Scholar
• Fichard A, Kleman JP, Ruggiero F. (1995). Another look at collagen V and XI molecules. Matrix Biol 14:515–531.
   PubMed Web of Science ®Google Scholar
• Friedman SL. (2003). Liver fibrosis—from bench to bedside. J Hepatol 38 (Suppl 1):S38–S53.
   Google Scholar
• Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaissé JM. (2003). The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859–867.
   PubMed Web of Science ®Google Scholar
• Gefter ML, Margulies DH, Scharff MD. (1977). A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet 3:231–236.
   PubMedGoogle Scholar
• Gelse K, Pöschl E, Aigner T. (2003). Collagens—structure, function, and biosynthesis. Adv Drug Deliv Rev 55:1531–1546.
   PubMed Web of Science ®Google Scholar
• Gressner OA, Weiskirchen R, Gressner AM. (2007). Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 381:107–113.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, Klickstein L, Aggarwal P, Nemirovskiy O, Byrjalsen I, Qvist P, Bay-Jensen AC, Dam EB, Madsen SH, Christiansen C. (2009). Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14:181–202.
   PubMed Web of Science ®Google Scholar
• Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, Jiménez W. (2008). Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 324:475–483.
   PubMed Web of Science ®Google Scholar
• Osawa Y, Seki E, Adachi M, Taura K, Kodama Y, Siegmund SV, Schwabe RF, Brenner DA. (2006). Systemic mediators induce fibrogenic effects in normal liver after partial bile duct ligation. Liver Int 26:1138–1147.
   PubMedGoogle Scholar
• Ruggiero F, Champliaud MF, Garrone R, Aumailley M. (1994). Interactions between cells and collagen V molecules or single chains involve distinct mechanisms. Exp Cell Res 210:215–223.
   PubMedGoogle Scholar
• Schuppan D, Ruehl M, Somasundaram R, Hahn EG. (2001). Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21:351–372.
   PubMed Web of Science ®Google Scholar
• Segovia-Silvestre T, Reichenbach V, Ros J, Vassiliadis E, Barascuk N, Morales-Ruiz M, Karsdal MA, Jiménez W. (2010). CO3-610, a novel non-invasive serum marker of liver fibrosis and portal hypertension in carbon tetrachloride-treated rats. In review.
   Google Scholar
• Tsukadaa S, Parsonsb CJ, Rippe RA. (2006). Mechanisms of liver fibrosis. Clin Chim Acta 364:33–60.
   PubMedGoogle Scholar
• Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, Friedman SL, Carmeliet P, Jiménez W, Morales-Ruiz M. (2007). Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46:1919–1926.
   PubMed Web of Science ®Google Scholar
• Veidal SS, Bay-Jensen A-C, Tougas G, Karsdal MA, Vainer B. (2010). Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis Markers 28:15–28.
   PubMedGoogle Scholar
• Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA. (2010). Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 3:5.
   PubMedGoogle Scholar
• Weiler-Normann C, Herkel J, Lohse AW. (2007). Mouse models of liver fibrosis. Z Gastroenterol 45:43–50.
   PubMedGoogle Scholar
• Wynn TA. (2008). Cellular and molecular mechanisms of fibrosis. J Pathol 214:199–210.
   PubMed Web of Science ®Google Scholar